NYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis $94.24 -0.14 (-0.14%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Glaukos Stock (NYSE:GKOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Glaukos alerts:Sign Up Key Stats Today's Range$93.28▼$94.9150-Day Range$90.99▼$106.6552-Week Range$77.10▼$163.71Volume315,608 shsAverage Volume912,679 shsMarket Capitalization$5.39 billionP/E RatioN/ADividend YieldN/APrice Target$134.67Consensus RatingModerate Buy Company Overview Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Read More Glaukos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreGKOS MarketRank™: Glaukos scored higher than 88% of companies evaluated by MarketBeat, and ranked 124th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 10 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageGlaukos has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Glaukos' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -39.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -39.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Glaukos' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.23% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Glaukos has recently increased by 24.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-0.90 Percentage of Shares Shorted9.23% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Glaukos has recently increased by 24.87%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.05 News SentimentGlaukos has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Glaukos this week, compared to 7 articles on an average week.Search Interest4 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Glaukos to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Glaukos' insider trading history. Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Stock News HeadlinesContrasting Glaukos (NYSE:GKOS) & Paradigm Medical Industries (OTCMKTS:PDMI)July 21, 2025 | americanbankingnews.comGlaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30July 9, 2025 | finance.yahoo.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 25 at 2:00 AM | Porter & Company (Ad)Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies - MorningstarJune 27, 2025 | morningstar.comMGlaukos Corporation: Glaukos Announces EU MDR Certification for iStent infinite and Other Leading MIGS TherapiesJune 26, 2025 | finanznachrichten.deGlaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS TherapiesJune 25, 2025 | businesswire.comGlaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing BellJune 25, 2025 | finance.yahoo.comGlaukos Corporation: Delivering Consistent GrowthJune 24, 2025 | seekingalpha.comSee More Headlines GKOS Stock Analysis - Frequently Asked Questions How have GKOS shares performed this year? Glaukos' stock was trading at $149.94 at the beginning of the year. Since then, GKOS stock has decreased by 37.0% and is now trading at $94.4140. How were Glaukos' earnings last quarter? Glaukos Corporation (NYSE:GKOS) posted its quarterly earnings results on Wednesday, April, 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business's revenue was up 24.6% compared to the same quarter last year. Read the conference call transcript. When did Glaukos IPO? Glaukos (GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Top institutional shareholders of Glaukos include Riverbridge Partners LLC (0.71%), Blair William & Co. IL (0.08%), Harbor Capital Advisors Inc. (0.07%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX). Company Calendar Last Earnings4/30/2025Today7/25/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSE:GKOS CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees780Year FoundedN/APrice Target and Rating Average Price Target for Glaukos$134.67 High Price Target$182.00 Low Price Target$72.00 Potential Upside/Downside+42.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.37 million Net Margins-31.40% Pretax Margin-30.40% Return on Equity-10.66% Return on Assets-8.06% Debt Debt-to-Equity Ratio0.09 Current Ratio6.49 Quick Ratio5.62 Sales & Book Value Annual Sales$383.48 million Price / Sales14.08 Cash FlowN/A Price / Cash FlowN/A Book Value$13.91 per share Price / Book6.79Miscellaneous Outstanding Shares57,140,000Free Float53,827,000Market Cap$5.40 billion OptionableOptionable Beta0.82 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSE:GKOS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.